When the pharmaceutical giant Allergan got FDA approval in 1989 to use Botulinum toxin for clinical use, it represented a medical breakthrough: the first time microbial bacteria was approved for injection into the human body. Better known as the protein that makes up the extremely deadly disease botulism, it would now be marketed as Botox. Now, 30 years later, it is one of the most popular clinical treatments in the world, with applications both cosmetic and therapeutic.
To commemorate 30 years of Botox, two executives from parent Allergan told Cheddar how the brand most commonly known as a wrinkle treatment has morphed into a miracle drug of sorts, with 11 separate therapeutic applications, from overactive bladder to excessive sweating to chronic migraines. More than 100 million vials of Botox have been manufactured worldwide.
"The majority of sales in the U.S. are therapeutic," said Jag Dosanjh, senior vice president of specialty therapeutics at Allergan. "And the markets are growing."
The FDA approved Botox for use in treatment of chronic migraine sufferers back in 2010, and that has become one of its biggest markets now, Dosanjh said. Since then, it has also been approved for urinary incontinence and crow's feet wrinkles. And there's more applications currently being studied, including a possible treatment for major depressive order, according to Dr. Mitchell Brin, Allergan's chief scientific officer for Botox and neurotoxins.
"There are significant regulatory hurdles," Brin said, though that's typical anytime a pharmaceutical company is "breaking new ground."
If you're not a migraine sufferer or excessive sweater (Botox is also a popular treatment for underarm perspiration), you probably know Botox mostly for its popularity as an anti-aging procedure. Kris Jenner is giving Botox treatments as a Christmas gift this year, and doctors report a dramatic increase in people under 30 asking about injections.
Dosanjh and Brin confirmed to Cheddar that millennials are a growing market for Botox, which is perhaps surprising given the generational trend toward body positivity.
Thirty years ago, it may have been hard to imagine that injecting literal botulism toxins into one's face would become so popular. But Botox's efficacy, safety, and status as the market leader has proven it to be a resilient, multi-faceted product.
"If you can connect with the patient in the right way, because the unmet need is so significant... there's still a lot of opportunity," said Dosanjh.
Wealthfront’s CFO Alan Iberman talks the $2.05B IPO and the major moment for robo banking as the company bets on AI, automation, and “self-driving money."
A rare magnum of Dom Pérignon Vintage 1961 champagne that was specially produced for the 1981 wedding of Prince Charles and Lady Diana has failed to sell during an auction. Danish auction house Bruun Rasmussen handled the bidding Thursday. The auction's house website lists the bottle as not sold. It was expected to fetch up to around $93,000. It is one of 12 bottles made to celebrate the royal wedding. Little was revealed about the seller. The auction house says the bids did not receive the desired minimum price.
The New York Times and President Donald Trump are fighting again. The news outlet said Wednesday it won't be deterred by Trump's “false and inflammatory language” from writing about the 79-year-old president's health. The Times has done a handful of stories on that topic recently, including an opinion column that said Trump is “starting to give President Joe Biden vibes.” In a Truth Social post, Trump said it might be treasonous for outlets like the Times to do “FAKE” reports about his health and "we should do something about it.” The Republican president already has a pending lawsuit against the newspaper for its past reports on his finances.
OpenAI has appointed Slack CEO Denise Dresser as its first chief of revenue. Dresser will oversee global revenue strategy and help businesses integrate AI into daily operations. OpenAI CEO Sam Altman recently emphasized improving ChatGPT, which now has over 800 million weekly users. Despite its success, OpenAI faces competition from companies like Google and concerns about profitability. The company earns money from premium ChatGPT subscriptions but hasn't ventured into advertising. Altman had recently announced delays in developing new products like AI agents and a personal assistant.
President Donald Trump says he will allow Nvidia to sell its H200 computer chip used in the development of artificial intelligence to “approved customers” in China. Trump said Monday on his social media site that he had informed China’s leader Xi Jinping and “President Xi responded positively!” There had been concerns about allowing advanced computer chips into China as it could help them to compete against the U.S. in building out AI capabilities. But there has also been a desire to develop the AI ecosystem with American companies such as chipmaker Nvidia.
